|
A Phase II Evaluation of Dose-Painted IMRT in Combination with
5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity
in Carcinoma of the Anal Cana
Histologically-proven, invasive primary squamous, basaloid, or
cloacogenic carcinoma of the anal canal; T stage 2-4 and N0-N3
stage; X-ray (PA and lateral), CT scan, or PET/CT scan of the chest
within 42 days prior to registration; CT scan, MRI, or PET/CT of
the abdomen and pelvis within 42 days prior to registration; Zubrod
Performance Status 0-1; Age > 18; Adequate bone marrow,
hepatic and renal function as defined in the protocol; Women of
childbearing potential and male participants must agree to use
a medically effective means of birth control throughout their participation
in the treatment phase of the study. If there is clinical suspicion
of AIDS, an HIV test must be done within 42 days prior to registration.
Note: HIV positive patients without AIDS are eligible for this
trial. Patients must sign a study-specific informed consent prior
to study entry.
IMRT
5-FU + Mitomycin-C on days 1 and 29
59
<< Back to Clinical
Trials Main Page >>
[ top ] |
